Pharmacological factors that influence the choice of inhaled corticosteroids

被引:24
作者
Edsbäcker, S [1 ]
机构
[1] Astra Zeneca R&D Lund, Expt Med, S-22187 Lund, Sweden
关键词
D O I
10.2165/00003495-199958004-00002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Local therapeutic effect relative to the risk of adverse effects of inhaled drugs, i.e. airway selectivity, is determined by the efficiency of the delivery system and the physicochemical and pharmacokinetic properties of the drug molecule. For the inhaled corticosteroid formulations, many of the pharmacokinetic prerequisites for airway selectivity have been fulfilled, but there are still differences that may influence the choice of treatment regimens. This choice should be based on disease severity, age, inhalation technique, preference and expected compliance, together with a knowledge of individual features of different corticosteroid formulations. Simple to use, hand-held pressurised or breath-actuated inhalers have favourable lung deposition properties and are appropriate for most patients. For small children or severely ill patients, nebulised treatment or spacers may be advocated. A corticosteroid formulation with a high intrinsic activity and long duration of action allows for once-daily administration in some patient groups; These properties may also partly compensate for noncompliance when more frequent administration schemes are used. The risk of adverse effects is reduced if systemic exposure is held to a minimum by rapid elimination and low tissue distribution.
引用
收藏
页码:7 / 16
页数:10
相关论文
共 64 条
[21]   A dose-response study comparing suppression of plasma cortisol induced by fluticasone propionate from Diskhaler and budesonide from Turbuhaler [J].
Grahnen, A ;
Jansson, B ;
Brundin, RM ;
LingAndersson, A ;
Lonnebo, A ;
Johansson, M ;
Eckernas, SA .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 52 (04) :261-267
[22]   STUDIES ON AN INTERMITTENT CORTICOSTEROID DOSAGE REGIMEN [J].
HARTER, JG ;
THORN, GW ;
REDDY, WJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1963, 269 (12) :591-&
[23]   STEROIDAL FATTY-ACID ESTERS [J].
HOCHBERG, RB ;
PAHUJA, SL ;
ZIELINSKI, JE ;
LARNER, JM .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1991, 40 (4-6) :577-585
[24]   Pharmacokinetic/pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model [J].
Hochhaus, G ;
Mollmann, H ;
Derendorf, H ;
GonzalezRothi, RJ .
JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 37 (10) :881-892
[25]  
HOGGER P, 1993, EUR RESP J S17, V6, P584
[26]   A DOUBLE-BLIND COMPARISON BETWEEN A NEW MULTIDOSE POWDER INHALER (TURBUHALER) AND METERED DOSE INHALER IN CHILDREN WITH ASTHMA [J].
HULTQUIST, C ;
AHLSTROM, H ;
KJELLMAN, NIM ;
MALMQVIST, LA ;
SVENONIUS, E ;
MELIN, S .
ALLERGY, 1989, 44 (07) :467-470
[27]   TOPICAL AND SYSTEMIC GLUCOCORTICOID POTENCIES OF BUDESONIDE AND BECLOMETHASONE DIPROPIONATE IN MAN [J].
JOHANSSON, SA ;
ANDERSSON, KE ;
BRATTSAND, R ;
GRUVSTAD, E ;
HEDNER, P .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1982, 22 (06) :523-529
[28]  
JOHNSON M, 1998, RESP DRUG DELIVERY, V6, P61
[29]   PULMICORT(R) TURBOHALER(R) ONCE-DAILY AS INITIAL PROPHYLACTIC THERAPY FOR ASTHMA [J].
JONES, AH ;
LANGDON, CG ;
LEE, PS ;
LINGHAM, SA ;
NANKANI, JP ;
FOLLOWS, RMA ;
TOLLEMAR, U ;
RICHARDSON, PDI .
RESPIRATORY MEDICINE, 1994, 88 (04) :293-299
[30]  
Källén A, 1999, AM J RESP CRIT CARE, V159, pA118